GOLDMAN SACHS GROUP INC - AMYLYX PHARMACEUTICALS INC ownership

AMYLYX PHARMACEUTICALS INC's ticker is and the CUSIP is 03237H101. A total of 135 filers reported holding AMYLYX PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.3%.

Quarter-by-quarter ownership
GOLDMAN SACHS GROUP INC ownership history of AMYLYX PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$21,736,313
-25.4%
1,187,128
-12.1%
0.00%
-33.3%
Q2 2023$29,129,810
-27.3%
1,350,478
-1.1%
0.01%
-33.3%
Q1 2023$40,083,487
+4.7%
1,366,172
+31.8%
0.01%0.0%
Q4 2022$38,290,176
+258.5%
1,036,270
+173.1%
0.01%
+350.0%
Q3 2022$10,680,000379,3990.00%
Other shareholders
AMYLYX PHARMACEUTICALS INC shareholders Q4 2022
NameSharesValueWeighting ↓
Perceptive Advisors 6,088,333$224,963,9046.32%
Alpha Wave Global, LP 821,220$30,344,0795.54%
Ghost Tree Capital, LLC 350,000$12,933,0005.52%
Boxer Capital, LLC 2,084,000$77,003,8004.06%
Altium Capital Management LP 140,000$5,173,0002.63%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 2,693,000$99,506,3502.06%
Iron Triangle Partners LP 240,240$8,876,8681.59%
EMERALD MUTUAL FUND ADVISERS TRUST 655,015$24,202,8041.50%
EMERALD ADVISERS, LLC 836,909$30,923,7881.49%
GREAT POINT PARTNERS LLC 190,000$7,020,5001.38%
View complete list of AMYLYX PHARMACEUTICALS INC shareholders